M-Life’s™ Molecular Systems Approach is Proving Itself as the Next Generation for Drug Discovery.
M-Life’s™ Molecular Systems Approach is Proving Itself as the Next Generation for Drug Discovery
NASHVILLE, TENNESSEE – M-LIFE™ announced the successful advancement of its anti-cancer prospect MLS-222QLD in preclinical testing. This molecule is one of several M-Life’s™ new generation of molecules aimed at the treatment of the most aggressive and untreatable forms of cancer. MLS-222QLD is a member of a new class of multi-targeting agent (MTA) cancer therapeutics that act upon both the cancer cellular mitosis and apoptosis pathways.
The latest results augment a wide range of prior successful animal and in vitro testing. M-Life’s Director of Translational Discovery Dr. John Panos said, “We’re excited about the rapid progress of MLS-222QLD. Previously, this molecule has been incredibly efficacious in the treatment of leukemic mice and in vitro glioblastoma multiforme. Now we have both the pharmacokinetics and hERG toxicity testing for MLS-222QLD that are likewise steller. In hERG testing MLS-222QLD showed no potential for hERG related cardiotoxicity. It’s rare that such active molecules have toxicity and pharmacokinetics profiles this favorable.”
The MLS-222QLD molecule is one of eight molecules being advanced by M-Life™ for the treatment of pediatric glioblastoma multiforme (GBM) and acute myeloid leukemia (AML). M-Life™ expects clinical trials to initiate in early 2023. Ted Moskal, M-Life™ Chief Executive Officer, said, “Obviously we’re very pleased with the progress of our cancer drug program. Pediatric GBM and AML are two highly aggressive forms of cancer for which there are limited treatment options. We believe that because of the uniqueness of our molecules as multi-targeting agents with botanical underpinnings, these molecules have the potential for use as frontline AML and GBM treatments. Perhaps more exciting, our platforms also indicate the suitability of MLS-222QLD and our other MTA molecules for the treatment of many other types of cancer.”
About M-Life™
M-Life™ is a life sciences, drug discovery company focusing on the development of new drugs via its proprietary integrated design platforms that simulate human efficacy, toxicity and side-effects in a virtual environment through artificial intelligence (AI) and machine learning (ML) proprietary algorithms. The Company is committed to the development of new frontline drugs that are more efficacious but with fewer side effects. The Company’s pipeline consists of non-addictive analgesics, anti-virals, anti-infectives, Alzheimer’s and anti-cancer prospective drugs. To learn more about M-Life™, please visit us at www.m-lifesciences.com.
Contact Information:
M-Life™
Ted Moskal
870.680.2141